Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

NCT04575194 on ClinicalTrials.gov · last registry update 2020-10-08

40 participants. Its estimated completion date, 30 September 2022, has passed with no update to the record. Primary outcome, as filed: Changes in blood pressure. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is approved in the US, but not for hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: National and Kapodistrian University of Athens
Sponsor type: Other
Enrollment: 40
Started: 2020-09-08
Primary completion: 2022-09-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Changes in blood pressure

Conditions studied

Obesity · Blood Pressure

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.